No registrations found.
Source
Brief title
Health condition
psoriasis
psoriatic arthritis
arthritis psoriatica
artritis psoriatica
psoriatic artritis
Sponsors and support
Intervention
No registrations found.
Outcome measures
Primary outcome
The prevalence of (newly discovered) PsA in known PsO patients in the setting of a university dermatology outpatient clinic, in total and stratified per treatment group
Secondary outcome
- The prevalence of complaints in the various domains of PsA in the newly discovered PsA patients
- The predictive value of joint complaints for the presence of PsA in PsO
- The predictive value of cutaneous parameters of PsO for the presence of PsA
- The predictive value of comorbidity for the presence of PsA in PsO
- The predictive value of entheseal/joint injury for the presence of PsA in PsO
- The predictive value of laboratory markers for the presence of PsA in PsO
- The predictive value of genetic markers for the presence of PsA in PsO
- The effect of referral to a rheumatology department on different disease domains and QoL
Background summary
Rationale: Psoriasis (PsO) is a common inflammatory skin disease. Besides the skin, it is recognized that this disease can affect multiple domains such as nails, joints and entheses. About 30% of the patients with PsO will develop symptoms in the musculoskeletal domains. Untreated inflammation in psoriatic arthritis (PsA) can lead to irreversible joint damage and further reduces quality of life. Since musculoskeletal involvement is often preceded by the dermatological symptoms of PsO, patients with pure cutaneous psoriasis (PsC) should be routinely screened for joint involvement. Current screening questionnaires, like the often used Psoriasis Epidemiology Screening Tool (PEST), offer a moderate discrimination between patients with PsA and PsC at best. Our aim is to assert the prevalence of known and previously undiagnosed PsA in a PsC cohort. By comparing the gathered data of the PsA and PsC patients, we hope to improve the screening of PsC patients, and to reduce both undertreatment of locomotor symptoms as well as unnecessary diagnostic investigations.
Objective: To ascertain the prevalence of PsA in a tertiary PsO cohort. Secondary objectives will be to ascertain the clinical features of these patients. With these features we want to find clinical, laboratory or genetic markers to predict the presence of PsA in PsO patients. Moreover, we wish to establish the added value of PsA screening for the quality of life (QoL) of PsO patients.
Study design: Multicenter cross-sectional study with a single follow-up visit after 1 year. Patients will be screened at baseline for PsA symptoms by a rheumatology resident and referred to a rheumatology clinic if deemed necessary. At baseline, several clinical and sociodemographic parameters will be assessed. We will collect blood samples for diverse biochemical studies and genomic DNA. Patients will be followed for 1 year after active screening for PsA. Quality of life (QoL) and treatment change will be recorded after this period, to assess the effect of screening and referral.
Study objective
We hypothesize that in current dermatological practice, there is a undisclosed burden of psoriatic arthritis in psoriasis patients. We wish to discover the prevalence of known and unknown arthritis in these patients, and find clinical and experimental predictors for comcommitant arthritis.
Study design
baseline, 1 year
Intervention
None
Inclusion criteria
* Diagnosis of cutaneous psoriasis
* Age 18 years or above
* Willing and able to comply with visits and study-related procedures
* Provide signed informed consent (IC)
Exclusion criteria
* Age below 18 years
* Unable to give IC
* Unable or unwilling to comply with visits and study-related procedures
* Participation in other trials involving psoriatic disease
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL7397 |
NTR-old | NTR7604 |
CCMO | NL68137.091.18 |